POSA56 A Cost-Effectiveness Analysis of Polatuzumab in Combination with Bendamustine and Rituximab in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma in Portugal

Autor:	B Pinheiro, M Cardoso, M Borges, A Launonen, R Ho, L Silva Miguel
Rok vydání:	2022
Předmět:	Health Policy Public Health Environmental and Occupational Health
Zdroj:	Value in Health. 25:S43-S44
ISSN:	1098-3015
DOI:	10.1016/j.jval.2021.11.201
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_________::a105a87ad49498d2dd59aaf924511346 https://doi.org/10.1016/j.jval.2021.11.201 Zobrazit plný text záznamu Full Text from ScienceDirect